Journal of Oncology

Journal of Oncology / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 2192378 | https://doi.org/10.1155/2020/2192378

Shanshan Ding, Jun Ma, Xingguo Song, Xiaohan Dong, Li Xie, Xianrang Song, Lisheng Liu, "Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy", Journal of Oncology, vol. 2020, Article ID 2192378, 13 pages, 2020. https://doi.org/10.1155/2020/2192378

Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy

Academic Editor: Reza Izadpanah
Received05 May 2020
Revised15 Jul 2020
Accepted08 Aug 2020
Published25 Aug 2020

Abstract

Background. Procalcitonin (PCT), C-reactive protein (CRP), and neutrophil-to-lymphocyte ratio (NLR) have emerged as important markers of inflammation, and these markers, especially PCT and CRP, have been studied in patients with neutropenia. This study was designed to evaluate their value in differentiating infectious fever from tumor fever (TF) and to investigate their role in assessing outcomes in nonneutropenic lung cancer patients (NNLCPs). Methods. This retrospective clinical study included 588 febrile NNLCPs between January 2019 and December 2019. The levels of PCT, CRP, and conventional inflammatory markers, including white blood cells (WBC) and neutrophils (NEU), were measured. NLR was defined as the ratio of the absolute neutrophil count to the absolute lymphocyte count. Patients’ clinical and bacteriological data were recorded. Results. This study included 311 NNLCPs with bacterial infections and 277 with TF. Inflammatory markers such as PCT, CRP, WBC, and NEU levels and NLR were significantly higher in patients with bacterial infections than in those with TF ( < 0.0001). However, PCT level was the best predictor of bacterial infections, with an area under the curve (AUC) of 0.874, followed by CRP level (AUC = 0.855) and NLR (AUC = 0.792) ( < 0.0001). Additionally, PCT level was significantly elevated in patients with bacterial infections with progressive disease after radiotherapy and chemotherapy ( < 0.01). Conclusions. The present study demonstrated the superiority of PCT over CRP and NLR in the diagnosis of febrile patients with bacterial infections. Additionally, PCT can be used to assess the clinical outcomes and cancer progression in NNLCPs.

1. Introduction

Patients with lung cancer are susceptible to bacterial infections owing to their compromised immune system [1], leading to high morbidity and mortality [2, 3]. Although neutropenia is known to be a major risk factor for infections [4], few studies have evaluated nonneutropenic lung cancer patients (NNLCPs). In NNLCPs, fever may be caused by bacterial infections or by tumor fever (TF) [5, 6]. Considering that immediate empirical antibiotic therapy has been widely recommended for febrile patients [1, 5], patients with nonbacterial infections might be exposed to unnecessary antibiotics. This excessive use of antibiotics can result in toxicity, bacterial resistance, increased patient mortality, and significant medical costs [5, 7]. Thus, a differential diagnosis of fever at the initial stage of therapy is important [8].

In such cases, bacterial infections in NNLCPs should be identified to provide appropriate and effective treatment. Most bacterial infections can be diagnosed based on clinical symptoms, inflammatory markers, radiological imaging, and microbiological data [1, 9]. Currently, conventional biomarkers such as white blood cell (WBC) count, neutrophil (NEU) count, erythrocyte sedimentation rate, and clinical signs and symptoms are not sufficiently sensitive and specific to guide treatment decisions for NNLCPs with fever [1012]. Moreover, as the gold standard for bacterial infections, microbiological cultures have certain disadvantages, including diagnostic delays (as a result of culture methods), suboptimal sensitivity (blood cultures), and low specificity due to contamination (sputum cultures) [10, 12, 13]. Therefore, reliable specific and sensitive markers are needed for NNLCPs with fever.

Several inflammatory markers have been evaluated for the diagnosis of infections. Procalcitonin (PCT), a precursor of the hormone calcitonin [5], has emerged as a promising marker for bacterial infections in various diseases [1418]. Some studies have shown that PCT might be superior to commonly used clinical variables and other laboratory tests in the diagnosis of infections [1922]. Most importantly, PCT level appears to correlate with the extent and severity of infection [2325]. C-reactive protein (CRP), another marker for diagnosing infections, is produced primarily by hepatocytes in response to infection [2]. Several studies have also indicated that PCT and CRP levels can be used to distinguish infectious fever from TF in patients with febrile neutropenia [5, 26, 27]. Neutrophil-to-lymphocyte ratio (NLR), the easily measured, reproducible, and inexpensive marker of disease [28], has been reported to be a diagnostic marker for cancer [2933]. Moreover, it is indicative of an impaired cell-mediated immunity associated with systemic inflammation [28], thus influenced by many conditions like metabolic disorder including diabetes mellitus and obesity [34]. It has been reported that an increased level of NLR in peripheral blood can predict the development of type 2 diabetes in morbid obese patients with high sensitivity and specificity. Thus, it has attracted attention in recent years. In addition, previous research had reported platelet count and platelet indices are the indicators of platelet function and activation, which have been evaluated for diagnosis of liver fibrosis [35]. Chronic inflammatory process is associated with neoplastic transformation; thus altered platelet count and platelet indices might serve as potential biomarkers for the diagnosis and prognosis of cancer [36]. In summary, many studies have evaluated the diagnostic utility of inflammatory markers in various diseases and have particularly assessed the role of PCT and CRP in patients with febrile neutropenia. However, their value as a diagnostic tool in NNLCPs needs further study.

Inflammation is an important marker of outcomes in cancer. Accumulating evidence has been found regarding the role of inflammatory markers in cancer development and progression [5, 28, 3739]. In a study that evaluated PCT level in patients with solid tumors and no evidence of infection, higher PCT level was found in patients with extensively metastatic cancer [40]. Thus, PCT level can be considered a predictor of clinical outcomes in patients with cancer without bacterial infections. Similarly, the CRP level has been studied for its predictive and prognostic value in various human malignancies [41, 42]. Some studies have found that PCT and CRP levels are associated with tumor stage [1, 40, 43] and that their levels are higher in patients with advanced tumors than in patients with early-stage cancer [5, 44, 45]. At the same time, the prognostic role of NLR has been documented in various cancers [4648]. For example, in patients with breast cancer, an elevated NLR typically indicates shorter disease-free survival and overall survival [49]. In summary, recent studies have confirmed a relationship between inflammatory markers and poor prognosis. To the best of our knowledge, however, few studies have investigated the role of these markers in assessing outcomes and in cancer progression in NNLCPs with bacterial infections.

Thus, in the present study, we first evaluated the diagnostic value of PCT, CRP, and NLR compared with conventional biomarkers such as WBC and NEU counts in determining bacterial infections in febrile NNLCPs. Next, we assessed their usefulness in predicting clinical outcomes and cancer progression in NNLCPs. The study findings should be validated in future studies with a higher number of patients.

2. Materials and Methods

2.1. Patient Eligibility and Classification

In this retrospective clinical observational study, we included 588 NNLCPs with fever who were admitted to Shandong Cancer Hospital and Institute from January 2019 to December 2019. Clinical characteristics were collected from the patients’ electronic medical records and the Ruimei laboratory information system version 6.0 (rmlis, Huangpu District, Shanghai, China).

Figure S1 shows 588 patients with nonneutropenic fever who were divided into two groups on the basis of their clinical, microbiological, and radiological data. The bacteria-infected group comprised 311 patients with microbiologically documented infection (MDI), which was defined as fever with positive bacterial cultures from specimens. The TF group comprised 277 patients without microbiological confirmation, radiological evidence, or clinically documented infections. Patients who met the following criteria were enrolled in this study: axillary temperature >37.5°C and absolute neutrophil count not lower than 0.5 × 109/L. Hematological parameters and inflammatory mediators such as PCT and CRP levels were determined within 48 h of the onset of fever, and bacterial cultures were taken. Prior to the start of antibiotic treatment, all measurements were performed. Patient diagnoses were confirmed via pathological examination. At the same time, patients with certain influential factors such as immune system disease, metabolic diseases, cardiovascular disease, the use of corticosteroid drugs, and the infection of other pathogenic microorganisms (e.g., virus, fungus, and parasite) were excluded.

2.2. Bacterial Culture and Identification

Bacterial cultures from specimens such as blood, mid-stream urine, sputum, and drainage fluid were prepared and analyzed. For blood cultures, blood samples were collected several times during the fever cycle. If the culture result was confirmed to be positive within 24 h, two or more blood samples were collected for analysis. Sputum and mid-stream urine were collected in the early morning. All specimens were collected before antibiotic treatment and were transferred to the laboratory within 1 h after collection. The results of bacterial cultures were considered as the gold standard for the diagnosis of infection. After bacterial cultures, biotypes were identified using the Biomerieux ATB Expression system, and biotypes that were commonly contaminated by a single culture and could not be excluded were eliminated. All procedures were conducted in accordance with the manufacturers’ instructions and the BC standards of the Clinical Laboratory Standards Institute [50].

2.3. Laboratory Measurement of Inflammatory Markers

The serum PCT level was determined by a quantitative electrochemiluminescence immunometric assay using a COBAS E602 analyzer (Roche Diagnostics GmbH, Mannheim, Germany), with level of <0.05 ng/mL considered normal.

Plasma CRP level was measured by immunoturbidimetry assay using Beckman Coulter analyzer AU5800 (Beckman Coulter, Brea, CA, USA). The reference value provided by the manufacturer was <10 mg/L.

For hematological studies, we collected whole blood in sterile tubes containing K2-ethylenediaminetetraacetic acid, and blood counts were estimated using automatic hematological analyzer Sysmex XN9000 (Sysmex Corporation, Kobe, Japan). Total peripheral leukocyte, lymphocyte, monocyte, and neutrophil levels were also recorded. NLR was defined as the ratio of the absolute neutrophil count to the absolute lymphocyte count. All tests were performed according to the manufacturer’s instructions.

2.4. Statistical Analysis

Statistical analysis was performed using SPSS version 22.0 statistical software (SPSS, Chicago, IL, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA). For comparisons of nonnormal continuous variables, the Mann–Whitney U test was used for two independent samples. Spearman’s correlation was used to compare the correlation between two variables. Receiver operating characteristic (ROC) curve analysis was implemented to evaluate the effects of markers for predicting bacterial infections. The optimal cut-off points were determined using the Youden index. Data were presented as the median ± interquartile range (range, minimum–maximum). Significance was established at  < 0.05.

3. Results

3.1. Patient Characteristics and Microbiology Results

A total of 588 NNLCPs were analyzed in this study (Figure S1). The clinical and demographic characteristics of the bacteria-infected group (N = 311) and TF group (N = 277) are shown in Table 1, including age, sex, pathological type of cancer, tumor stage, and hematological parameters. The median age was 65 (range, 35–87) years in the bacteria-infected group and 64 (range, 28–84) years in the TF group. Regarding the causative pathogens, seven patients were identified by MDI as having simultaneous infection with two types of bacteria; 318 cases in the bacteria-infected group had positive bacterial cultures, including 44 (13.8%) cases of Gram-positive bacteria and 274 (86.2%) cases of Gram-negative bacteria. No significant differences were found between Gram-positive bacteria and Gram-negative bacteria in PCT, CRP, WBC, NEU, and NLR levels (Table S1). Among Gram-positive bacteria, Staphylococcus aureus was the most common species (6.3%), followed by Streptococcus pneumoniae (4.7%). Among Gram-negative bacteria, the most frequently identified species were Klebsiella pneumoniae (21.4%) and Haemophilus influenzae (18.2%), followed by Pseudomonas aeruginosa (13.9%), Escherichia coli (9.4%), Acinetobacter baumannii (5.4%), and Moraxella catarrhalis (4.4%). Names of all the bacterial taxa are shown in Table 1.


CharacteristicsBacteria-infected group (N = 311)TF group (N = 277)

Age, median (range) (years)65 (35, 87)64 (28, 84)
Sex
 Male n (%)246 (79.1)189 (68.2)
 Female n (%)65 (20.9)88 (31.8)
Pathological type
 AC n (%)131 (42.1)139 (50.2)
 SCC n (%)106 (34.1)73 (26.4)
 SCLC n (%)54 (17.4)56 (20.2)
Others n (%)20 (6.4)9 (3.2)
 Tumor stage
 I n (%)55 (17.7)30 (10.8)
 II n (%)18 (5.8)13 (4.7)
 III n (%)84 (27.0)82 (29.6)
 IV n (%)135 (43.4)133 (48.0)
Not available, EMR n (%)19 (6.1)19 (6.9)
Hematological parameters
 WBC median (range) (109/L)8.87 (0.89, 42.54)5.57 (0.82, 29.36)
 LYM median (range) (109/L)0.83 (0.05, 6.07)1.11 (0.08, 8.14)
 NEU median (range) (109/L)7.15 (0.73, 41.32)3.82 (0.63, 23.21)
 MON median (range) (109/L)0.62 (0.02, 3.83)0.53 (0.04, 3.51)
 RBC median (range) (1012/L)3.87 (1.48, 5.50)4.02 (1.54, 5.72)
 Hb median (range) (g/L)120 (46, 169)124 (51, 172)
 PLT median (range) (109/L)202 (2, 567)217 (19, 772)
 NLR median (range)8.70 (0.83, 190.38)3.63 (0.69, 39.00)
 PLR median (range)226.83 (2.38, 1480.00)189.68 (10.58, 857.14)
 LMR median (range)1.45 (0.18, 62.50)1.98 (0.31, 22.44)
Microorganisma
 Gram-positive bacteria n (%)44 (13.8)
  Staphylococcus aureus n (%)20 (6.3)
  Streptococcus pneumoniae n (%)15 (4.7)
  Others n (%)9 (2.8)
 Gram-negative bacteria n (%)274 (86.2)
  Klebsiella pneumoniae n (%)68 (21.4)
  Haemophilus influenzae n (%)58 (18.2)
  Pseudomonas aeruginosa n (%)44 (13.9)
  Escherichia coli n (%)30 (9.4)
  Acinetobacter baumannii n (%)17 (5.4)
  Moraxella catarrhalis n (%)14 (4.4)
  Others n (%)43 (13.5)

aSeven patients were identified by MDI as having simultaneous infection with two types of bacteria. NNLCPs: nonneutropenic lung cancer patients; TF: tumor fever; AC: adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small cell lung cancer; EMR: electronic medical records; WBC: white blood cell; LYM: lymphocyte; NEU: neutrophil; MON: monocyte; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; MDI: microbiologically documented infection.
3.2. NLR Had a Greater Capacity for the Diagnosis of Bacterial Infections than WBC and NEU in NNLCPs with Fever

We first confirmed whether WBC and NEU levels and NLR could be used in the diagnosis of bacterial infections for NNLCPs as shown in the bacteria-infected and TF groups (Figure S1). Figure 1(a) shows that patients with MDI had a higher median WBC count (8.87 × 109/L) than with NNLCPs without bacterial infections (5.57 × 109/L) ( < 0.0001). A significant difference in the NEU level was found between the bacteria-infected (7.15 × 109/L) and TF groups (3.82 × 109/L) ( < 0.0001) (Figure 1(b)). As shown in Figure 1(c), patients with MDI had higher median NLR values (8.70) than patients with TF (3.63) ( < 0.0001).

To determine the diagnostic accuracy of WBC, NEU, and NLR in bacterial infections, we constructed ROC curves. The analysis revealed that in NNLCPs with MDI, WBC had a discriminative power, with an AUC of 0.718 (95% confidence interval [CI] 0.677–0.759), sensitivity of 62.1%, and specificity of 72.9% compared with the TF group. For NEU, the AUC was 0.748 (95% CI 0.709–0.787), with 61.1% sensitivity and 78.3% specificity. Meanwhile, the ROC curves indicated that NLR had an AUC of 0.786 (95% CI 0.749–0.823), with 57.2% sensitivity and 90.6% specificity (Figure 1(d)).

3.3. Comparison of PCT, CRP, and NLR for Bacterial Infections in Febrile NNLCPs

In order to achieve better diagnostic accuracy, the classic inflammatory markers PCT and CRP were used. A total of 125 eligible patients were screened for their PCT and CRP levels. 69 patients were assigned to the bacteria-infected subgroup A, and the remaining 56 were assigned to the TF subgroup A (Figure S1).

The median level and range of blood inflammatory markers (PCT, CRP, WBC, NEU, and NLR) in the two subgroups are shown in Table 2. These markers differed between the subgroups. There was a markedly significant difference in the median PCT level between bacteria-infected subgroup A (0.24 ng/mL) and TF subgroup A (0.05 ng/mL) ( < 0.0001) (Figure 2(a)). Similarly, the median CRP level of bacteria-infected subgroup A (53.2 mg/L) was higher than that of TF subgroup A (6.3 mg/L) ( < 0.0001) (Figure 2(b)). Furthermore, bacteria-infected patients had higher median WBC and NEU levels (8.49 × 109/L and 7.39 × 109/L, respectively) than patients with nonbacterial infections (5.24 × 109/L and 3.56 × 109/L, respectively,  < 0.0001) (Figures 2(c) and 2(d)). Figure 2(e) shows that the patients who had positive bacterial cultures had higher median NLR values (12.15) than the patients with TF with nonneutropenic lung cancer (3.27) ( < 0.0001).


VariableBacteria-infected subgroup A (N = 69)TF subgroup A (N = 56) value Mann–Whitney

PCT median (range) (ng/mL)0.24 (0.04, 18.62)0.05 (0.02, 1.58)a<0.0001
CRP median (range) (mg/L)53.2 (0.6, 358.3)6.3 (0.2, 89.4)<0.0001
WBC median (range) (109/L)8.49 (1.1, 42.54)5.24 (1.89, 15.82)<0.0001
NEU median (range) (109/L)7.39 (0.73, 41.32)3.56 (0.96, 13.94)<0.0001
NLR median (range)12.15 (1.03, 189.80)3.27 (0.69, 39.00)<0.0001

aNot to overestimate possible differences between the two groups, the values reported as <0.02 by the laboratory were noted as “0.02” for statistical analysis. NNLCPs: nonneutropenic lung cancer patients; TF: tumor fever; PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cell; NEU: neutrophil; NLR: neutrophil-to-lymphocyte ratio.

Table 3 shows Spearman’s correlations among the test parameters in bacteria-infected subgroup A. As expected, the circulating markers of inflammation tended to be significantly correlated. However, WBC level was not correlated with PCT and CRP levels (Spearman’s r = 0.222,  = 0.067 and r = 0.176,  = 0.148, respectively).


PCTCRPWBCNEUNLR

PCT
r1.000.7460.2220.2850.511
 95% CI0.605 to 0.838−0.029 to 0.4480.045 to 0.4990.293 to 0.685
<0.0010.0670.017<0.001
CRP
r1.000.1760.2580.497
 95% CI−0.058 to 0.3980.031 to 0.4690.297 to 0.666
0.1480.032<0.001
WBC
r1.000.9780.547
 95% CI0.955 to 0.9860.378 to 0.673
<0.001<0.001
NEU
r1.000.682
 95% CI0.559 to 0.776
<0.001
NLR
r1.00
 95% CI

r Correlation coefficient calculated using Spearman’s methods. TF: tumor fever; PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cell; NEU: neutrophil; NLR: neutrophil-to-lymphocyte ratio.

To evaluate the discriminative power of inflammatory markers to predict infections in subgroup A of nonneutropenic lung cancer, we constructed ROC curves. Table 4 shows the evaluation of AUC, sensitivity, specificity, negative predictive value, positive predictive value, and the Youden index. These cut-off values were calculated based on the best sensitivity and specificity (Youden index), which were found to have the highest diagnostic value for predicting bacterial infections. Figure 2(f) shows that of the inflammatory markers, PCT was the best predictor, with an AUC of 0.874 (95% CI 0.813–0.935), followed by CRP, with an AUC of 0.855 (95% CI 0.790–0.919). On comparison of the patients with MDI with the noninfected patients, the ROC curves of WBC, NEU, and NLR showed that the AUC was 0.729 (95% CI 0.639–0.818), 0.761 (95% CI 0.676–0.846), and 0.792 (95% CI 0.712–0.872), respectively.


Diagnostic performancePCTCRPWBCNEUNLR

AUC0.8740.8550.7290.7610.792
95% CI0.813–0.9350.790–0.9190.639–0.8180.676–0.8460.712–0.872
Cut-off value0.105 ng/mL12.2 mg/L5.975 × 109 L6.245 × 109 L7.397
Sensitivity79.7%85.5%78.3%62.3%66.7%
Specificity80.4%71.4%64.3%82.1%87.5%
PPV83.3%78.7%73.0%81.1%86.8%
NPV76.3%80.0%70.6%63.9%68.1%
Youden index0.6010.5690.4250.4450.542
value<0.001<0.001<0.001<0.001<0.001

TF: tumor fever; AUC, area under the ROC curve; PPV: positive predictive value; NPV: negative predictive value; PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cell; NEU: neutrophil; NLR: neutrophil-to-lymphocyte ratio.
3.4. PCT Level Was Elevated in NNLCPs with Bacterial Infections and Progressive Disease (PD)

To study blood inflammatory markers for clinical outcome assessment in NNLCPs, we analyzed the relationship between response to therapy and the levels of inflammatory markers in bacteria-infected subgroup A and TF subgroup A.

As shown in Table 5, patients with MDI were treated with various therapies, including radiotherapy [30], chemotherapy [15], surgery [19], and others (targeted combination, conservative treatment, or suspension therapy) [5]. Twenty-five patients in bacteria-infected subgroup A received radiotherapy; of these, 13 developed PD, 11 patients had stable disease (SD), and 1 showed partial response (PR). In terms of response to radiotherapy, patients with PD-radiotherapy (response to radiotherapy was PD) had higher PCT level than patients with non-PD-radiotherapy (response to radiotherapy was SD and PR) ( = 0.0116) (Figure 3). Remarkably, no differences were found between patients with PD-radiotherapy and those with non-PD-radiotherapy in CRP level and NLR (data not shown). However, the CRP level and NLR were higher in the PD-radiotherapy group than in the non-PD-radiotherapy group. Three patients had PD and 12 had SD after chemotherapy in bacteria-infected subgroup A. Owing to the small sample size, statistical differences were not analyzed.


Response to therapyTotal
PDSDPRunknown

Bacteria-infected subgroup A (N = 69)
Treatment
 Radiotherapy13111530
 Chemotherapy3120015
 Surgery19
 Othersa5
TF subgroup A (N = 56)
Treatment
 Radiotherapy2134827
 Chemotherapy0103821
 Surgery1
 Othersa7

aRefer mainly to targeted combination, conservative treatment, or suspension therapy. TF: tumor fever; PD: progressive disease; SD: stable disease; PR: partial response.

Next, we evaluated the inflammatory marker levels for clinical response assessment in TF subgroup A. Detailed treatment methods and outcomes of this group are shown in Table 5. Of the 27 patients who received radiotherapy, 2 had PD, 13 had SD, and 4 had PR, whereas 8 had no clear efficacy evaluation according to Response Evaluation Criteria In Solid Tumors guidelines [51]. Of the 21 patients who underwent chemotherapy, except those for whom the efficacy was not clear, 10 had SD and 3 showed PR. However, statistical differences between the levels of inflammatory markers and response to therapy were not analyzed owing to the small sample size.

3.5. PCT Can Be Used to Assess Clinical Outcomes for NNLCPs with Bacterial Infections

Collectively, based on the existing studies, a correlation between PCT level and clinical response was identified and then expanded to other patients for future validation. Because of the low number of PCT measurements conducted in the TF group, no further research was conducted. Therefore, we screened all patients with MDI tested for PCT and analyzed the relationship between outcomes and inflammatory markers in bacterial-infected group B (N = 191) (Figure S1).

Given the good correlation between PCT and the other inflammatory markers described above, we classified patients according to PCT values measured on presentation with MDI in bacteria-infected subgroup B. As shown in Table 6, categorization according to PCT level revealed clear distinctions with respect to WBC and NEU levels and NLR, all of which were significantly higher in the high PCT group than in the low PCT group.


VariableHigh PCT group (≥0.23 ng/mL) median (range)Low PCT group (<0.23 ng/mL) median (range) value Mann–Whitney

PCT (ng/mL)0.67 (0.23, 100)a0.09 (0.03, 0.23)<0.0001
WBC (109/L)11.61 (1.1, 42.54)8.84 (2.82, 26.24)0.0124
NEU (109/L)9.73 (0.73, 41.32)6.905 (1.35, 22.65)0.0011
NLR14.42 (1.14, 190.38)6.485 (1.03, 66.79)<0.0001

aNot to overestimate possible differences between the two groups, the values reported as > 100 by the laboratory were noted as “100” for statistical analysis. PCT: procalcitonin; NEU: neutrophil; NLR: neutrophil-to-lymphocyte ratio.

As described in Table 7, of 191 patients with MDI, 62 received radiotherapy, 50 received chemotherapy, 66 underwent surgical treatment, and 13 were referred mainly to targeted combination therapy, conservative treatment, or suspension therapy. Of the 62 patients receiving radiotherapy, 45 had a clear efficacy evaluation. Of these, 20 had PD, 23 had SD, and 2 had PR. In particular, PCT level was higher in the PD-radiotherapy group than in the non-PD-radiotherapy group of bacteria-infected subgroup B ( = 0.0002) (Figure 4(a)).


Response to therapyTotal
PDSDPRunknown

Treatment191
 Radiotherapy202321762
 Chemotherapy142131250
 Surgery66
 Othersa13

aRefer mainly to targeted combination, conservative treatment, or suspension therapy. PD: progressive disease; SD: stable disease; PR: partial response.

Of the 38 patients who received chemotherapy and had clear efficacy, 14 had PD, 21 had SD, and 3 showed PR. According to the outcomes, PCT level of patients with lung cancer with PD (PD-chemotherapy) was higher than that of patients with non-PD-chemotherapy (the response to chemotherapy was SD and PR) in bacteria-infected subgroup B ( = 0.0057) (Figure 4(b)).

Although other inflammatory markers were not significantly different between patients with PD and non-PD following Mann–Whitney tests analysis (data not shown), their levels tended to be higher in the PD group than in the non-PD group. Collectively, our data support our conclusion that PCT level can be used to assess the outcomes of bacteria-infected NNLCPs.

4. Discussion

It is estimated that almost 50% of patients with solid tumors and 60% of patients with hematological malignancies die from infectious complications [45], in which neutropenia is an important risk factor for infection [4]. However, few studies have evaluated the role of inflammatory markers in predicting infections in febrile NNLCPs.

In our study, the febrile episodes were retrospectively classified into bacterial infections with MDI and TF. Our data demonstrated that PCT, CRP, WBC, and NEU levels and NLR were predictive of infectious fever in NNLCPs. There were significant differences in these inflammatory markers between the nonneutropenic patients with infection and those with TF. Our results are consistent with those of previous reports [26, 27], which could be helpful in identifying the cause of fever in NNLCPs and guide appropriate and effective antibiotic treatment [52]. To evaluate the discriminative power of inflammatory markers to distinguish between infectious fever and TF, we plotted ROC curves. The sensitivity, specificity, and best cut-off values for clinical use were also presented. Compared with CRP level, NLR, PCT level could more effectively distinguish between TF and infectious fever. ROC analysis indicated that PCT level was the best predictor for bacterial infections in NNLCPs, demonstrating the highest AUC, followed by CRP level and NLR. Although conventional blood inflammatory parameters such as WBC and NEU levels are easily measured and inexpensive [28], they have limited discriminative power and utility for predicting infections. These findings are consistent with those of previous studies. It has been reported that PCT had the better discriminative power than CRP to differentiate not only TF from LBI (localized bacterial infection) (AUC was 0.840 for PCT and 0.786 for CRP) [1], but also bacteremia from nonbacteremia in cancer patients with febrile neutropenia (AUC was 0.748 for PCT and 0.655 for CRP) [53], as well as bacterial infection from other causes of fever in pediatric oncology patients with febrile neutropenia (AUC was 0.769 for PCT and 0.596 for CRP) [54].

However, some reports have indicated that the usefulness of these markers in the diagnosis of infectious diseases in clinical practice is disputable. One study retrospectively evaluated the value of PCT level for infectious fever and TF in febrile episodes in patients with cancer [55]. Although PCT level in the former group appeared to be higher than that in the latter group, this difference was not statistically confirmed [56]. It was also reported that neither the PCT test nor the CRP test was used to diagnose the cause of febrile neutropenia, except in cases of severe sepsis [57, 58]. It is possible that these inconsistent findings could be attributed to the heterogeneity of the enrolled patients: their study mainly focused on hematological malignancies with febrile neutropenia, whereas we aimed to evaluate the diagnostic role of inflammatory markers for infections in febrile NNLCPs. On the other hand, the fact that the patients were divided into two groups based on the presence or absence of bacterial infections with MDI in our study, in contrast to that in other studies, represents an important limitation of our study.

As mentioned above, the use of inflammatory markers as biomarkers for diagnosing bacterial infections has been previously discussed [1418]. Studies have shown that these markers are helpful in distinguishing various types of infections. For example, PCT and CRP levels were higher in patients with bacterial pneumonia infected with Gram-negative bacteria than in those infected with Gram-positive bacteria; this finding could aid clinicians in determining the appropriate use of antibiotics as a supplementary means [2]. Similarly, some authors have found higher PCT level in cases of Gram-negative bacterial infections at the onset of fever compared with those in cases of Gram-positive bacterial infections or TF, whereas the other biomarkers did not show significance in children and adult patients with febrile neutropenia [52, 59, 60]. The lipopolysaccharide (LPS) structure of the outer membrane of Gram-negative bacteria may be responsible for this phenomenon. The endotoxin LPS can not only induce inflammatory response and cytokine production, but also elevate the expression of PCT at the mRNA and protein levels dependent on nuclear transcription factor κB (NF-κB) [61]. Unfortunately, among Gram-negative and Gram-positive cultures isolated in our study, no significant differences were observed between the two types of bacteria in inflammatory markers in NNLCPs, perhaps due to the different patient profiles or inclusion and exclusion criteria.

As far as clinical outcomes are concerned, little is currently known about the relationship between inflammatory markers and cancer progression in NNLCPs with bacterial infections. Previous reports focused on the value in assessing the efficacy of antibiotic treatment in patients with bacterial infections [45]. It was shown that inflammatory marker levels after fever onset were significantly lower than those at fever onset in patients who exhibited a response to antibiotic therapy [5]. Thus, we analyzed the value of inflammatory marker levels for clinical response assessment. In the study of patients with bacterial infections, for PCT, the outcome evaluation ability considerably improved when we expanded the sample size to 191. The results showed that PCT could predict disease progression for NNLCPs with infections. In contrast, neither CRP level nor NLR had a correlation with clinical outcomes, nor did NEU or WBC levels. For NEU and WBC levels, low reliability and susceptibility limited the study [62]. For CRP level, the small sample size was the limiting factor; however, its level was higher in nonsurvivors than in survivors. Therefore, we do not deny the value of CRP level in outcome assessments in an expanded cohort. For NLR, neutrophils and lymphocytes can be affected by various factors, including bacterial infections, radiochemotherapy, and autoimmunity [28], which hinder outcome assessments in patients with inflammation. With regard to noninfected patients, an analysis was not performed due to the low number of available studies. However, our data demonstrated that patients with TF mainly had SD after anticancer treatments, whereas patients with febrile infections had poorer clinical treatment responses, which strengthens the usefulness of inflammatory markers in outcome assessment in NNLCPs.

Additionally, considering that inflammatory markers can predict cancer progression [5, 3133], PCT and CRP levels and NLR in patients with TF were compared by lung cancer stages. Our results showed no significant differences, but the values tended to be higher in patients with stage IV than in those with Stages I–III lung cancer (Figure S2). A report indicated that cancer stages were related to CRP level and not to PCT level [43]. In the absence of a bacterial infection, nonspecific elevation of PCT level can occur in situations of massive stress [13, 63]. These inconsistent findings point to the need for further research in patients with lung cancer with no signs of infection.

Although the usefulness for diagnosis of bacterial infections and outcome assessment in patients with febrile nonneutropenic lung cancer has been partially confirmed, several limitations should be considered in the present study. First, given it was a retrospective study with a small number of patients, the effect of confounding variables cannot be ruled out [5]. Prospective studies involving a larger sample size are required to draw generally applicable conclusions. Second, inflammatory markers were measured only at the onset of fever, which could lead to overlooking any subsequent increases in infected patients [64]. The value of dynamic rather than absolute values should be considered in the assessment of febrile episodes in NNLCPs. Third, the high heterogeneity of enrolled patients or our inclusion and exclusion criteria could have affected our results. For example, only patients who did not have severe neutropenia (ANC < 500) were recruited while other neutropenic patients with ANC 500–1500 were indeed included. At the same time, mounting evidence suggests that high body mass index (BMI), obesity, diabetes, liver cirrhosis, and CKD were able to affect procalcitonin levels. However, in the current study the lung cancer patients complicated with obesity, diabetes, liver cirrhosis, and CKD were excluded, since these cases were rare. Besides, we did not analyze the relationship between BMI and procalcitonin, because body weights were affected by tumor occupying intensely and obviously and we failed to collect detailed information of patient’s weight at the time of sample collecting. Finally, we relied on positive bacterial cultures from specimens to determine infections. However, there could have been false-negative bacterial culture results because of the sensitivity of the testing technique [5, 65]. Thus, we cannot completely rule out the possibility of infections in the TF group.

5. Conclusion

Overall, the present study demonstrated the superiority of PCT over CRP and NLR in differentiating infectious fever from TF. Additionally, markedly increased PCT level indicated a poorer treatment response and supported our conclusion that the PCT level can help predict the clinical outcome and cancer progression in NNLCPs. Further studies are needed to fully evaluate our findings.

Abbreviations

NNLCPs:Nonneutropenic lung cancer patients
TF:Tumor fever
WBC:White blood cell
NEU:Neutrophil
CRP:C-reactive protein
NLR:Neutrophil-to-lymphocyte ratio
PCT:Procalcitonin
MDI:Microbiologically documented infection
ROC:Receiver operating characteristic
PD:Progressive disease
SD:Stable disease
PR:Partial response.

Data Availability

The retrospective data used to support the findings of this study are included within the article.

Ethical Approval

This retrospective study was reviewed and approved by the Shandong Cancer Hospital Ethics Committee and was conducted according to the ethical guidelines of the Declaration of Helsinki of 1975. All patients in this study obtained informed consent.

Conflicts of Interest

No authors report any conflicts of interest.

Authors’ Contributions

LL, XiaS, and LX gave guidance on study concept and design. SD and XD were responsible for acquisition and collection of data. SD was responsible for data processing, statistical analysis, and drafting of the manuscript. JM and XinS gave instructions for manuscript writing and language modification. SD and LL performed manuscript revision. All authors read and approved the final manuscript supervision.

Acknowledgments

This work was supported by the Shandong Provincial Key Research and Development Program (2017CXGC1207 and 2016GSF201162), Jinan Clinical Medical Science and Technology Innovation Program (201704080), Wu Jieping Medical Fund (no. 320.6750.19088-24).

Supplementary Materials

Figure S1: schematic of patients’ recruitment and classification for study. TF: tumor fever; PCT: procalcitonin; CRP: C-reactive protein; NNLCPs: nonneutropenic lung cancer patients. Figure S2: Comparison of PCT and CRP levels and NLR in patients with stage I to III and stage IV in TF subgroup A. There was no significant difference in PCT (A) and CRP (B) levels and NLR (C) between patients with stage IV (n = 31) and those with I to III (n = 21) in TF subgroup A. ns: no significance; TF: tumor fever; PCT: procalcitonin; CRP: C-reactive protein; NLR: neutrophil-to-lymphocyte ratio. Supplementary Table 1: the levels of PCT (ng/mL), CRP (mg/L), WBC (109/L), NEU (109/L) and NLR, in microbiologically documented infections, distinguishing Gram-positive and Gram-negative. (Supplementary Materials)

References

  1. Z. Zhao, X. Li, Y. Zhao et al., “Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients,” Medicine, vol. 97, no. 33, Article ID e11930, 2018. View at: Publisher Site | Google Scholar
  2. J. H. Tang, D. P. Gao, and P. F. Zou, “Comparison of serum PCT and CRP levels in patients infected by different pathogenic microorganisms: a systematic review and meta-analysis,” The Brazilian Journal of Medical and Biological Research, vol. 51, no. 7, Article ID e6783, 2018. View at: Publisher Site | Google Scholar
  3. T. Berghmans, J.-P. Sculier, and J. Klastersky, “A prospective study of infections in lung cancer patients admitted to the hospital,” Chest, vol. 124, no. 1, pp. 114–120, 2003. View at: Publisher Site | Google Scholar
  4. J. Reyna-Figueroa, A. Lagunas-Martinez, P. Martinez Matsumoto, and V. Madrid-Marina, “Procalcitonin as a diagnostic biomarker of sepsis in children with cancer, fever and neutropenia: literature review,” Archivos Argentinos de Pediatria, vol. 113, no. 1, pp. 46–52, 2015. View at: Google Scholar
  5. W. Shomali, R. Hachem, A.-M. Chaftari et al., “Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?” Cancer, vol. 118, no. 23, pp. 5823–5829, 2012. View at: Publisher Site | Google Scholar
  6. J. A. Zell and J. C. Chang, “Neoplastic fever: a neglected paraneoplastic syndrome,” Supportive Care in Cancer, vol. 13, no. 11, pp. 870–877, 2005. View at: Publisher Site | Google Scholar
  7. S. E. Cosgrove, “The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs,” Clinical Infectious Diseases, vol. 42, no. Supplement_2, pp. S82–S89, 2006. View at: Publisher Site | Google Scholar
  8. S. Hangai, Y. Nannya, and M. Kurokawa, “Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases,” Leukemia & Lymphoma, vol. 56, no. 4, pp. 910–914, 2015. View at: Publisher Site | Google Scholar
  9. H. E. Davies, R. J. O. Davies, C. W. H. Davies, and B. T. S. P. D. G. Group, “Management of pleural infection in adults: British thoracic society pleural disease guideline 2010,” Thorax, vol. 65, no. Suppl 2, pp. ii41–ii53, 2010. View at: Publisher Site | Google Scholar
  10. H. Lee, “Procalcitonin as a biomarker of infectious diseases,” The Korean Journal of Internal Medicine, vol. 28, no. 3, pp. 285–291, 2013. View at: Publisher Site | Google Scholar
  11. L. R. Baden, W. Bensinger, M. Angarone et al., “Prevention and treatment of cancer-related infections,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 11, pp. 1412–1445, 2012. View at: Publisher Site | Google Scholar
  12. X. Liu, D. F. Wang, Y. Fang, W. F. Ye, S. Liu, and N. Lou, “Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia,” Leukemia & Lymphoma, vol. 56, no. 1, pp. 85–91, 2015. View at: Publisher Site | Google Scholar
  13. P. Schuetz, W. Albrich, and B. Mueller, “Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future,” BMC Medicine, vol. 9, p. 107, 2011. View at: Publisher Site | Google Scholar
  14. S. Schuttrumpf, L. Binder, T. Hagemann, D. Berkovic, L. Trumper, and C. Binder, “Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations,” Clinical Infectious Diseases, vol. 43, no. 4, pp. 468–473, 2006. View at: Publisher Site | Google Scholar
  15. Y. Kurimura, S. Takahashi, Y. Hiyama et al., “Significance of procalcitonin measurement in cases with febrile condition during chemotherapy for urological cancer,” Hinyokika Kiyo, vol. 61, no. 4, pp. 141–145, 2015. View at: Google Scholar
  16. F. J. McCann, S. J. Chapman, W. C. Yu, N. A. Maskell, R. J. Davies, and Y. C. Lee, “Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings,” PLoS One, vol. 7, no. 12, Article ID e49894, 2012. View at: Publisher Site | Google Scholar
  17. B. Uzzan, R. Cohen, P. Nicolas, M. Cucherat, and G.-Y. Perret, “Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis,” Critical Care Medicine, vol. 34, no. 7, pp. 1996–2003, 2006. View at: Publisher Site | Google Scholar
  18. B. M. Tang, G. D. Eslick, J. C. Craig, and A. S. McLean, “Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 7, no. 3, pp. 210–217, 2007. View at: Publisher Site | Google Scholar
  19. E. D. Carrol, A. P. J. Thomson, and C. A. Hart, “Procalcitonin as a marker of sepsis,” International Journal of Antimicrobial Agents, vol. 20, no. 1, pp. 1–9, 2002. View at: Publisher Site | Google Scholar
  20. W.-H. Hahn, J.-H. Song, H. Kim, and S. Park, “Is procalcitonin to C-reactive protein ratio useful for the detection of late onset neonatal sepsis?” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 31, no. 6, pp. 822–826, 2018. View at: Publisher Site | Google Scholar
  21. A. Luzzani, E. Polati, R. Dorizzi, A. Rungatscher, R. Pavan, and A. Merlini, “Comparison of procalcitonin and C-reactive protein as markers of sepsis,” Critical Care Medicine, vol. 31, no. 6, pp. 1737–1741, 2003. View at: Publisher Site | Google Scholar
  22. B. Muller, S. Harbarth, D. Stolz et al., “Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia,” BMC Infectious Diseases, vol. 7, p. 10, 2007. View at: Publisher Site | Google Scholar
  23. S. Harbarth, K. Holeckova, C. Froidevaux et al., “Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 3, pp. 396–402, 2001. View at: Publisher Site | Google Scholar
  24. J. Schröder, K.-H. Staubach, P. Zabel, F. Stüber, and B. Kremer, “Procalcitonin as a marker of severity in septic shock,” Langenbeck’s Archives of Surgery, vol. 384, no. 1, pp. 33–38, 1999. View at: Publisher Site | Google Scholar
  25. C. A. Gogos, E. Drosou, H. P. Bassaris, and A. Skoutelis, “Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options,” The Journal of Infectious Diseases, vol. 181, no. 1, pp. 176–180, 2000. View at: Publisher Site | Google Scholar
  26. K. A. Thursky and L. J. Worth, “Can mortality of cancer patients with fever and neutropenia be improved?” Current Opinion in Infectious Diseases, vol. 28, no. 6, pp. 505–513, 2015. View at: Publisher Site | Google Scholar
  27. K. S. Massaro, S. F. Costa, C. Leone, and D. A. Chamone, “Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults,” BMC Infectious Diseases, vol. 7, p. 137, 2007. View at: Publisher Site | Google Scholar
  28. S. S. Faria, P. C. Fernandes Jr., M. J. Silva et al., “The neutrophil-to-lymphocyte ratio: a narrative review,” Ecancermedicalscience, vol. 10, p. 702, 2016. View at: Google Scholar
  29. C. A. Dumitru, K. Moses, S. Trellakis, S. Lang, and S. Brandau, “Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology,” Cancer Immunology, Immunotherapy, vol. 61, no. 8, pp. 1155–1167, 2012. View at: Publisher Site | Google Scholar
  30. W. K. Xiao, D. Chen, S. Q. Li, S. J. Fu, B. G. Peng, and L. J. Liang, “Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis,” BMC Cancer, vol. 14, p. 117, 2014. View at: Publisher Site | Google Scholar
  31. Q. C. B. S. Thio, W. A. Goudriaan, S. J. Janssen et al., “Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases,” British Journal of Cancer, vol. 119, no. 6, pp. 737–743, 2018. View at: Publisher Site | Google Scholar
  32. S. Diem, S. Schmid, M. Krapf et al., “Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab,” Lung Cancer, vol. 111, pp. 176–181, 2017. View at: Publisher Site | Google Scholar
  33. M. Stotz, A. Gerger, F. Eisner et al., “Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer,” British Journal of Cancer, vol. 109, no. 2, pp. 416–421, 2013. View at: Publisher Site | Google Scholar
  34. H. Yilmaz, B. Ucan, M. Sayki et al., “Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 9, no. 4, pp. 299–304, 2015. View at: Publisher Site | Google Scholar
  35. T. Milovanovic Alempijevic, M. Stojkovic Lalosevic, I. Dumic et al., “Diagnostic accuracy of platelet count and platelet indices in noninvasive assessment of fibrosis in nonalcoholic fatty liver disease patients,” Canadian Journal of Gastroenterology and Hepatology, vol. 2017, Article ID 6070135, 5 pages, 2017. View at: Publisher Site | Google Scholar
  36. X. Zhu, Y. Cao, P. Lu et al., “Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer,” Scientific Reports, vol. 8, no. 1, Article ID 11814, 2018. View at: Publisher Site | Google Scholar
  37. G. J. K. Guthrie, K. A. Charles, C. S. D. Roxburgh, P. G. Horgan, D. C. McMillan, and S. J. Clarke, “The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer,” Critical Reviews in Oncology/Hematology, vol. 88, no. 1, pp. 218–230, 2013. View at: Publisher Site | Google Scholar
  38. J. M. Jones, N. C. McGonigle, M. McAnespie, G. W. Cran, and A. N. Graham, “Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer,” Lung Cancer, vol. 53, no. 1, pp. 97–101, 2006. View at: Publisher Site | Google Scholar
  39. M. Hara, Y. Matsuzaki, T. Shimuzu et al., “Preoperative serum C-reactive protein level in non-small cell lung cancer,” Anticancer Research, vol. 27, no. 4C, pp. 3001–3004, 2007. View at: Google Scholar
  40. V. Matzaraki, K. I. Alexandraki, K. Venetsanou et al., “Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis,” Clinical Biochemistry, vol. 40, no. 5-6, pp. 336–342, 2007. View at: Publisher Site | Google Scholar
  41. H. J. Nielsen, I. J. Christensen, I. J. Christensen, S. Sørensen, F. Moesgaard, and N. Brünner, “Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer,” Annals of Surgical Oncology, vol. 7, no. 8, pp. 617–623, 2000. View at: Publisher Site | Google Scholar
  42. B. Tulek, H. Koylu, F. Kanat, U. Arslan, and F. Ozer, “Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients,” Współczesna Onkologia, vol. 1, no. 1, pp. 68–72, 2013. View at: Publisher Site | Google Scholar
  43. V. Avrillon, M. Locatelli-Sanchez, L. Folliet et al., “Lung cancer may increase serum procalcitonin level,” Infectious Disorders—Drug Targets, vol. 15, no. 1, pp. 57–63, 2015. View at: Publisher Site | Google Scholar
  44. A. M. Chaftari, R. Hachem, R. Reitzel et al., “Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection,” PLoS One, vol. 10, no. 7, Article ID e0130999, 2015. View at: Publisher Site | Google Scholar
  45. A. Sbrana, M. Torchio, G. Comolli, A. Antonuzzo, M. Danova, and Italian Network for Supportive Care in Oncology (NICSO), “Use of procalcitonin in clinical oncology: a literature review,” New Microbiologica, vol. 39, no. 3, pp. 174–180, 2016. View at: Google Scholar
  46. S. Mallappa, A. Sinha, S. Gupta, and S. J. D. Chadwick, “Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer,” Colorectal Disease, vol. 15, no. 3, pp. 323–328, 2013. View at: Publisher Site | Google Scholar
  47. T. Gondo, J. Nakashima, Y. Ohno et al., “Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy,” Urology, vol. 79, no. 5, pp. 1085–1091, 2012. View at: Publisher Site | Google Scholar
  48. X. An, P.-R. Ding, Y.-H. Li et al., “Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer,” Biomarkers, vol. 15, no. 6, pp. 516–522, 2010. View at: Publisher Site | Google Scholar
  49. J. Chen, Q. Deng, Y. Pan et al., “Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer,” FEBS Open Bio, vol. 5, no. 1, pp. 502–507, 2015. View at: Publisher Site | Google Scholar
  50. Y. Shi, B. Du, Y. C. Xu, X. Rui, W. Du, and Y. Wang, “Early changes of procalcitonin predict bacteremia in patients with intensive care unit-acquired new fever,” Chinese Medical Journal, vol. 126, no. 10, pp. 1832–1837, 2013. View at: Google Scholar
  51. H. Watanabe, M. Okada, Y. Kaji et al., “New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1),” Gan To Kagaku Ryoho, vol. 36, no. 13, pp. 2495–2501, 2009. View at: Google Scholar
  52. G. Fleischhack, I. Kambeck, D. Cipic, C. Hasan, and U. Bode, “Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II,” British Journal of Haematology, vol. 111, no. 4, pp. 1093–1102, 2000. View at: Publisher Site | Google Scholar
  53. D. Y. Kim, Y.-S. Lee, S. Ahn, Y. H. Chun, and K. S. Lim, “The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia,” Cancer Research and Treatment, vol. 43, no. 3, pp. 176–180, 2011. View at: Publisher Site | Google Scholar
  54. K. G. E. Miedema, E. S. J. M. de Bont, R. F. M. O. Elferink et al., “The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia,” Supportive Care in Cancer, vol. 19, no. 10, pp. 1593–1600, 2011. View at: Publisher Site | Google Scholar
  55. K. Scheinpflug, E. Schalk, E. Grabert, and H. J. Achenbach, “Procalcitonin is not useful to discriminate between infectious and noninfectious CRP elevation in patients with non-small cell lung cancer,” Infection Control & Hospital Epidemiology, vol. 36, no. 9, pp. 1117-1118, 2015. View at: Publisher Site | Google Scholar
  56. N. Penel, C. Fournier, S. Clisant, and M. N’Guyen, “Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever,” Supportive Care in Cancer, vol. 12, no. 8, pp. 593–598, 2004. View at: Publisher Site | Google Scholar
  57. H. Giamarellou, E. J. Giamarellos-Bourboulis, P. Repoussis et al., “Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study,” Clinical Microbiology and Infection, vol. 10, no. 7, pp. 628–633, 2004. View at: Publisher Site | Google Scholar
  58. M. Aimoto, H. Koh, T. Katayama et al., “Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia,” Infection, vol. 42, no. 6, pp. 971–979, 2014. View at: Publisher Site | Google Scholar
  59. B. Bruno, A. Busca, S. Vallero et al., “Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients,” Expert Review of Hematology, vol. 10, no. 6, pp. 543–550, 2017. View at: Publisher Site | Google Scholar
  60. M. Svaldi, J. Hirber, A. I. Lanthaler et al., “Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients,” British Journal of Haematology, vol. 115, no. 1, pp. 53–57, 2001. View at: Publisher Site | Google Scholar
  61. Y. Bai, J. Lu, Y. Cheng et al., “NF-small ka, CyrillicB increases LPS-mediated procalcitonin production in human hepatocytes,” Scientific Reports, vol. 8, no. 1, p. 8913, 2018. View at: Publisher Site | Google Scholar
  62. T. Südhoff, A. Giagounidis, and M. Karthaus, “Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice,” Chemotherapy, vol. 46, no. 2, pp. 77–85, 2000. View at: Publisher Site | Google Scholar
  63. R. Aabenhus and J.-U. S. Jensen, “Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet?” Primary Care Respiratory Journal, vol. 20, no. 4, pp. 360–367, 2011. View at: Publisher Site | Google Scholar
  64. Y. Sakr, C. Sponholz, F. Tuche, F. Brunkhorst, and K. Reinhart, “The role of procalcitonin in febrile neutropenic patients: review of the literature,” Infection, vol. 36, no. 5, pp. 396–407, 2008. View at: Publisher Site | Google Scholar
  65. N. Mancini, S. Carletti, N. Ghidoli, P. Cichero, R. Burioni, and M. Clementi, “The era of molecular and other non-culture-based methods in diagnosis of sepsis,” Clinical Microbiology Reviews, vol. 23, no. 1, pp. 235–251, 2010. View at: Publisher Site | Google Scholar

Copyright © 2020 Shanshan Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views401
Downloads212
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.